---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-26-000028"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2026-08-05T10:33:07+00:00"
generated_at: "2026-08-05T10:35:22.659997+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Reports Q2 2026 Revenue of $783.3M, Net Income Up 8% to $333M

## Summary
- Total revenues decreased 2% year-over-year to $783.3M; net income rose 8% to $333.0M.
- Tyvaso DPI revenues grew 4% to $326.6M; Nebulized Tyvaso fell 18% to $126.0M.
- Submitted NDAs for ralinepag tablets in PAH and Nebulized Tyvaso in IPF; potential approvals in 2027.
- Repurchased ~2.76M shares under $1.5B ASR agreements; $500M remaining in buyback program.
- R&D expense increased 9% to $146.3M driven by cardiopulmonary projects and contingent consideration.

## SEC filing metadata
- accession: 0001082554-26-000028
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2026-08-05T10:33:07+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/0001082554-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/uthr-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-26-000028
- JSON: https://secwatch.observer/filing/0001082554-26-000028.json
- Plain text: https://secwatch.observer/filing/0001082554-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.